This excellent paper describes a fascinating piece of work examining an aspect of clinical trials about which we know surprisingly little. Like all good research, the answers it provides lead to additional questions for future exploration. Participants in the UK-based Taxotere as Adjuvant Chemotherapy (TACT) trial, comparing a taxane-based regimen with one of two anthracycline-containing non-taxane regimens were approached during the follow-up period, before trial results were available, to seek their preferences about dissemination of the trial results to themselves and their relatives.
More: continued here
No Comments so far ↓
There are no comments yet...Kick things off by filling out the form below.